CORDIS
EU research results

CORDIS

English EN
European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry

European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry

Objective

The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors and to improve efficiency and on- and off-target toxicity are current challenges Therefore the EN-ACTI2NG program aims 1) to train PhD students with expertise in development of new and improved T cell-mediated cancer immuno-therapies; 2) to endow the PhD students with the ability to establish efficient communication between the academic and industrial research environments and between scientists and the general public; 3) to improve T cell mediated anti-cancer immuno-therapy by the identification and development of new cancer-specific immune receptors and enhancing their function by identifying and modifying their molecular mechanism of action. To reach these objectives we have designed individual research projects ranging from biophysical analysis of immune receptors, via molecular modification of their structure and testing their tumor killing capacity in cell-based and pre-clinical assays to product development. Secondments will assure that each PhD student will be exposed to these complementary approaches and that there will be synergic feedback between the projects, producing innovative results that could otherwise not be achieved. Extensive training in research-specific skills, career development and a continuous training in communication skills will allow the PhD students to become facilitators of the process of transformation of scientific innovation into products with social and economic value. As such, the EN-ACTI2NG program should contribute to overcoming the more general challenge of converting the European Community into an innovation-driven society.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Address

Calle Serrano 117
28006 Madrid

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 247 872,96

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

Germany

EU Contribution

€ 249 216,48

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 62 304,12

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 255 374,28

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 255 934,08

TECHNISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 255 934,08

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

Spain

EU Contribution

€ 247 872,96

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 273 287,88

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 249 216,48

STRATEC CONSUMABLES GMBH

Austria

EU Contribution

€ 255 934,08

KLINIKUM DER UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 159 221,64

Partners (2)

Sort alphabetically

Expand all

CELLULAR THERAPEUTICS LIMITED

SCIENSEED SL

Project information

Grant agreement ID: 721358

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 512 169,04

  • EU contribution

    € 2 512 169,04

Coordinated by:

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain